HIV Pharmacology: Barriers to the Eradication of HIV from the CNS

REFERENCES

• Lambotte 0, Deiva K, Tardieu M. HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathol. 2003;13:95–103.
   PubMed Web of Science ®Google Scholar
• Haas DW, Clough LA, Johnson BW, et al. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses. 2000;16:1491–1502.
   PubMed Web of Science ®Google Scholar
• Schrager LK, D'Souza MP. Cellular and anatomical reser-voirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA. 1998;280:67–71.
   PubMed Web of Science ®Google Scholar
• Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med. 2000;6:76–81.
   PubMed Web of Science ®Google Scholar
• Dybul M, Daucher M, Jensen MA, et al. Genetic character-ization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy. J Virol. 2003;77:3229–3237.
   PubMed Web of Science ®Google Scholar
• Portegies P, Enting RH, de Gans J, et al. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS. 1993;7:669–675.
   PubMed Web of Science ®Google Scholar
• Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology. 1994;44:1892–1900.
   PubMed Web of Science ®Google Scholar
• Foudraine NA, Hoetelmans RMW, Lange JMA, et al. Cere-brospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet. 1998;351:1547–1551.
   PubMed Web of Science ®Google Scholar
• Haas DW, Johnson BW, Spearman P, et al. Two phases of HIV RNA decay in CSF during initial days of multidrug therapy. Neurology. 2003;61:1391–1396.
   PubMed Web of Science ®Google Scholar
• Ho DD, Rota TR, Schooley RT, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodefi-ciency syndrome. N Engl J Med. 1985;313:1493–1497.
   PubMed Web of Science ®Google Scholar
• Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS. 2004;18:1101–1108.
   PubMed Web of Science ®Google Scholar
• Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Nati Acad Sci USA. 1998;95:8869–8873.
   PubMed Web of Science ®Google Scholar
• Eggers C, Hertogs K, Sturenburg HJ, van Lunzen J, Stellbrink HJ. Delayed central nervous system virus sup-pression during highly active antiretroviral therapy is asso-ciated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetra-tion. AIDS. 2003; 17(13):1897–1906.
   PubMed Web of Science ®Google Scholar
• Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK. Independent evolution of human immunode-ficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol. 2004;78:10133–10148.
   PubMed Web of Science ®Google Scholar
• Cinque P, Bestetti A, Morelli P, Presi S. Molecular analysis of cerebrospinal fluid: potential for the study of HIV-1 infec-tion of the central nervous system. J Neurovirol. 2000;6\(suppl 1):S95–S102.
   PubMed Web of Science ®Google Scholar
• Garcia F, Niebla G, Romeu J, et al. Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication. AIDS. 1999;13:1491–1496.
   PubMed Web of Science ®Google Scholar
• Harrington PR, Haas DW, Ritola K, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol. 2005;79:7959–7966.
   PubMed Web of Science ®Google Scholar
• Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–1300.
   PubMed Web of Science ®Google Scholar
• Koenig S, Gendelman HE, Orenstein JM, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS pa-tients with encephalopathy. Science. 1986;233:1089–1093.
   PubMed Web of Science ®Google Scholar
• Gartner S, Markovits P, Markovitz DM, Betts RF, Popovic M. Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA. 1986;256:2365–2371.
   PubMed Web of Science ®Google Scholar
• Williams KC, Corey S, Westmoreland SV, et al. Perivascu-lar macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med. 2001;193:905–915.
   PubMed Web of Science ®Google Scholar
• Salemi M, Lamers SL, Yu S, de Oliveira T, Fitch WM, McGrath MS. Phylodynamic analysis of human immunode-ficiency virus type 1 in distinct brain compartments pro-vides a model for the neuropathogenesis of AIDS. J Virol. 2005;79:11343–11352.
   PubMed Web of Science ®Google Scholar
• Killebrew DA, Troelstrup D, Valcour V, et al. Discordant plasma and cerebral spinal fluid cytokines/chemokines in relation to HIV-1-associated dementia. Cell Mol Biol (Noisy-le-grand). 2005;51(suppl):0L745–754.
   Google Scholar
• Hoetelmans RMW. Sanctuary sites in HIV-1 infection. Antivir Ther. 1998;3\(suppl 4):13–17.
   PubMed Web of Science ®Google Scholar
• Pomerantz RJ. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Biomed Pharmacother. 200155: 7–15.
   Google Scholar
• Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials. 2002;3(1):27–35.
   PubMedGoogle Scholar
• Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:238–243.
   PubMed Web of Science ®Google Scholar
• Staprans S, Marlowe N, Glidden D, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evi-dence for variable compartmentalization of infection. AIDS. 1999;13:1051–1061.
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Gamst AC, Capparelli E, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology. 2000;54:927–936.
   PubMed Web of Science ®Google Scholar
• Taylor S, Pereira A. Penetration of HIV-1 protease inhibi-tors into CSF and semen. HIV Med. 2000;1\(suppl 2):18–22.
   PubMedGoogle Scholar
• Enting RH, Hoetelmans RM, Lange JMA, Burger AM, Beijnen JH, Portegies P. Antiretroviral drugs and the cen-tral nervous system. AIDS. 1998;12:1941–1955.
   PubMed Web of Science ®Google Scholar
• Thomas SA, Segal MB. The passage of azido-deoxythymidine into and within the central nervous sys-tem: does it follow the parent compound, thymidine? J Pharmacol Exp Ther. 1997;281:1211–1218.
   Google Scholar
• Kim RB. Drug transporters in HIV therapy. Top HIV Med. 2003;11:136–139.
   PubMedGoogle Scholar
• Letendre SL, Ellis RJ, Grant I, McCutchan JA, and the HNRC Group. The CSF concentration/1C50 ratio: a poten-tial predictor of antiretroviral efficacy in the CNS. In: Pro-gram and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections; February 4–8, 2001; Chicago, Illinois. Abstract 614.
   Google Scholar
• Berger JR, Avison M. The blood brain barrier in HIV infec-tion. Front Biosci. 2004;9:2680–2685.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol. 2000;20:131–147.
   PubMed Web of Science ®Google Scholar
• Dallasta LM, Pisarov LA, Esplen JE, et al. Blood-brain barrier tight junction disruption in human immunodefi-ciency virus-1 encephalitis. Am J Pathol. 1999;155:1915–1927.
   PubMed Web of Science ®Google Scholar
• Saunders NR, Habgood MD, Dziegielewska KM. Barrier mechanisms in the brain, I. Adult brain. Clin Exp Pharmacol Physiol. 1999;26:11–19.
   PubMed Web of Science ®Google Scholar
• Thomas SA. Anti-HIV drug distribution to the central ner-vous system. Curr Pharm Des. 2004;10:1313–1324.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005;10:241–273.
   PubMedGoogle Scholar
• Kearney BP, Aweeka FT. The penetration of anti-infectives into the central nervous system. Neurol Clin. 1999;17:883–900.
   PubMed Web of Science ®Google Scholar
• Gisslén M, Norkrans G, Svennerholm B, Hagberg L. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis. 1997;175:434–437.
   PubMed Web of Science ®Google Scholar
• Lupia RH, Ferencz N, Lertora JJL, et al. Comparative phar-macokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. Antimicrob Agents Chemother. 1993;37:818–824.
   PubMed Web of Science ®Google Scholar
• Rolinski B, Bogner JR, Sadri I, Wintergerst U, Goebel FD. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J Acquir Im-mune Defic Syndr Hum Retrovirol. 1997;15:192–197.
   Web of Science ®Google Scholar
• Yang Z, Brundage RC, Barbhaiya RH, Sawchuk RJ. Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat. Pharm Res. 1997;14:865–872.
   PubMed Web of Science ®Google Scholar
• Zhang L, Price R, Aweeka F, Bellibas SE, Sheiner LB. Making the most of sparse clinical data by using a predic-tive-model-based analysis, illustrated with a stavudine pharmacokinetic study. Europ J Pharmaceut Sci. 200112: 377–385.
   Google Scholar
• McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, Stein DS. Pharmacokinetics of [14C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse tran-scriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother. 1999;43:2855–2861.
   PubMed Web of Science ®Google Scholar
• Capparelli EV, Letendre SL, Ellis RJ, Patel P, Holland D, McCutchan JA. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother. 2005;49:2504–2506.
   PubMed Web of Science ®Google Scholar
• Lanier ER, Sturge G, McClernon D, et al. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS. 200115: 747–751.
   Google Scholar
• Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, 2'3'-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem. 2002; 80:392–404.
   PubMed Web of Science ®Google Scholar
• Tomaszewski JE, Grieshaber CK, Balzarini J, et al. Toxico-logic and pharmacokinetic evaluation of 2',3'-dideoxycytidine (ddCyd, NSC-606170), a potential drug to treat AIDS. Proc Am Assoc Canc Res. 1987;28:440. Ab-stract 1743.
   Web of Science ®Google Scholar
• Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs. 2002;16:595–609.
   PubMed Web of Science ®Google Scholar
• Saavedra-Lozano J, McCoig C, Cao Y, et al. Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro. Antimicrobial Agents and Chemotherapy. 2004;48:8.
   Web of Science ®Google Scholar
• Antoniou T, Park-Wyllie LY, Tseng AL. Tenofovir: a nucle-otide analog for the management of human immunodefi-ciency virus infection. Pharmacotherapy. 2003;23:29–43.
   PubMed Web of Science ®Google Scholar
• Tashima K, Caliendo AM, Ahmad M. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected pa-tients receiving combination therapy. J Infect Dis. 1999;180:862–864.
   PubMed Web of Science ®Google Scholar
• Staszewski S, Morales-Ramirez J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865–1873.
   PubMed Web of Science ®Google Scholar
• Glynn SL, Yazdanian M. In vitro blood-brain barrier perme-ability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci. 1998;87:306–310.
   PubMed Web of Science ®Google Scholar
• Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs. 2002;16:595–609.
   PubMed Web of Science ®Google Scholar
• Kearney B, Price R, Sheiner L, et al. Estimation of nevirapine exposure within the cerebrospinal fluid using CSF: plasma area under the curve ratios. In: Program and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Illinois. Abstract 406.
   Google Scholar
• Tashima KT, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) sup-pression and efavirenz drug concentrations in HIV-1-in-fected patients receiving combination therapy. J Infect Dis. 1999;180:862–864.
   PubMed Web of Science ®Google Scholar
• Aweeka FT, Jayewardene A, Staprans S, et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:39–43.
   PubMedGoogle Scholar
• Gisolf EH, Enting RH, Jurriaans S, et al. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine. AIDS. 2000;14:1583–1589.
   PubMed Web of Science ®Google Scholar
• Scheid WM. Drug delivery to the central nervous system: general principles and relevance to therapy for infections of the central nervous system. Rev Infect Dis. 1989;11\(suppl 7):S1669–S1690.
   PubMedGoogle Scholar
• Martin C, Sönnerborg A, Svensson JO, Stahle L. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS. 1999;13:1227–1232.
   PubMed Web of Science ®Google Scholar
• Haas DW, Johnson B, Nicotera J, et al. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob Agents Chemother. 2003;47:2131–2137.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Sadler M, Buss N. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combi-nation antiretroviral therapy. Clin Infect Dis. 1999;28:403–404.
   PubMed Web of Science ®Google Scholar
• Haas D, Clough L, Johnson B, et al. Quantification of nelfinavir (NFV) and its active metabolite (M8) in CSF and plasma, and correlation with CSF HIV-1 RNA response. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, California. Abstract 313.
   Google Scholar
• Murphy R, Currier J, Gerber J, et al. Antiviral activity and pharmacokinetics of amprenavir with or without zidovudine/3TC in the cerebrospinal fluid of HIV-infected adults. In: Program and abstracts of the Seventh Confer-ence on Retroviruses and Opportunistic Infections; Janu-ary 30-February 2, 2000; San Francisco, California. Ab-stract 314.
   Google Scholar
• Capparelli EV, Holland D, Okamoto C, et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% in-hibitory concentration for HIV. AIDS. 2005;19:949–952.
   PubMed Web of Science ®Google Scholar
• McArthur JC, McClernon DR, Cronin MF, et al. Relation-ship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol. 1997;42:689–698.
   PubMed Web of Science ®Google Scholar
• Langford TD, Letendre SL, Larrea GJ, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol. 2003;13:195–210.
   PubMed Web of Science ®Google Scholar
• Neuenburg JK, Brodt HR, Herndier BG, et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 200231: 171–177.
   PubMed Web of Science ®Google Scholar
• Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004;56:416–423.
   PubMed Web of Science ®Google Scholar
• Antinori A, Giancola ML, Grisetti S. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS. 2002;16:1867–1876.
   PubMed Web of Science ®Google Scholar
• von Giesen HJ, Koller H, Theisen A, Arendt G. Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2002;29:363–367.
   PubMed Web of Science ®Google Scholar
• Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antivi-ral immune responses and antiretroviral therapy. Annu Rev Immunol. 2000;18:665–708.
   PubMed Web of Science ®Google Scholar
• Coull JJ, Romerio F, Sun J-M, et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol. 2000;74:6790–6799.
   PubMed Web of Science ®Google Scholar
• Coull JJ, He G, Melander C, Rucker VC, Dervan PB, Margolis DM. Targeted derepression of the human immu-nodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. J Virol. 2002;76:12349–12354.
   PubMed Web of Science ®Google Scholar
• He G, Margolis DM. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 acti-vator Tat. Mo/ Cell Biol. 2002;22:2965–2973.
   Web of Science ®Google Scholar
• Ylisastigui L, Coull JJ, Rucker VC, et al. Polyamides reveal a role for repression in viral latency within resting T cells of HIV-infected donors. J Infect Dis. 2004:190:1429–1437.
   PubMed Web of Science ®Google Scholar
• Demonte D, Quivy V, Colette Y, Van Lint C. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol. 2004;68: 1231–1238.
   PubMed Web of Science ®Google Scholar
• Fraser C, Ferguson NM, Ghani AC, et al. Reduction of the HIV-1-infected T-cell reservoir by immune activation treat-ment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS. 2000;14:659–669.
   PubMed Web of Science ®Google Scholar